#AS­CO22: A small Chi­na biotech play­er makes its de­but at AS­CO with promis­ing da­ta on its GPRC5D mul­ti­ple myelo­ma drug

With all the head­lines jump­ing out of AS­CO this year, you’d be for­giv­en for over­look­ing the up­beat da­ta com­ing from a low-pro­file Chi­nese biotech. But it’s worth a close sec­ond look.

Shang­hai-based Ori­Cell, a pri­vate play­er, has high­light­ed a round of promis­ing Phase I re­sults for its per­son­al­ized GPRC5D-di­rect­ed CAR-T OriCAR-017. Di­rect­ed at a small group of treat­ment-re­sis­tant pa­tients suf­fer­ing from mul­ti­ple myelo­ma, the biotech re­port­ed a 100% over­all re­sponse rate with 60% strin­gent CRs.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE